- Home
- PLX vs ELVA Comparison
PLX vs ELVA Comparison
Compare PLX & ELVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ELVA
- Stock Information
- Founded
- PLX 1993
- ELVA 1996
- Country
- PLX United States
- ELVA Canada
- Employees
- PLX N/A
- ELVA N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ELVA
- Sector
- PLX Health Care
- ELVA
- Exchange
- PLX Nasdaq
- ELVA Nasdaq
- Market Cap
- PLX 122.6M
- ELVA 125.5M
- IPO Year
- PLX 1998
- ELVA N/A
- Fundamental
- Price
- PLX $1.37
- ELVA $3.91
- Analyst Decision
- PLX Strong Buy
- ELVA Strong Buy
- Analyst Count
- PLX 1
- ELVA 5
- Target Price
- PLX $15.00
- ELVA $6.10
- AVG Volume (30 Days)
- PLX 1.3M
- ELVA 78.0K
- Earning Date
- PLX 08-13-2025
- ELVA 08-12-2025
- Dividend Yield
- PLX N/A
- ELVA N/A
- EPS Growth
- PLX N/A
- ELVA N/A
- EPS
- PLX 0.05
- ELVA N/A
- Revenue
- PLX $59,764,000.00
- ELVA $48,016,000.00
- Revenue This Year
- PLX $65.02
- ELVA $55.29
- Revenue Next Year
- PLX $57.34
- ELVA $63.69
- P/E Ratio
- PLX $28.34
- ELVA N/A
- Revenue Growth
- PLX 0.18
- ELVA N/A
- 52 Week Low
- PLX $0.82
- ELVA $1.67
- 52 Week High
- PLX $3.10
- ELVA $4.07
- Technical
- Relative Strength Index (RSI)
- PLX 41.78
- ELVA 67.96
- Support Level
- PLX $1.43
- ELVA $3.11
- Resistance Level
- PLX $1.54
- ELVA $3.89
- Average True Range (ATR)
- PLX 0.09
- ELVA 0.21
- MACD
- PLX 0.01
- ELVA 0.04
- Stochastic Oscillator
- PLX 5.77
- ELVA 83.33
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.